Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphaide therapy in advanced ovarian adenocarcinoma
- 15 July 1994
- Vol. 74 (2) , 656-663
- https://doi.org/10.1002/1097-0142(19940715)74:2<656::aid-cncr2820740218>3.0.co;2-6
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: A gynecologic oncology group studyGynecologic Oncology, 1992
- Long-term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancerGynecologic Oncology, 1992
- Sequential cisplatin-doxorubicin, early debulking surgery and intraperitoneal chemotherapy in advanced ovarian cancerEuropean Journal Of Cancer, 1992
- Long-term survival in ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1991
- Tumor reduction surgery and long-term survival in advanced ovarian cancer: A DACOVA studyGynecologic Oncology, 1990
- Primary surgical therapy of ovarian cancer: How much and whenGynecologic Oncology, 1990
- Long-Term Follow-Up of Patients with Advanced Ovarian Carcinoma Treated with Debulking Surgery and Chemotherapy Consisting of Cisplatin, Doxorubicin, and CyclophosphamideOncology, 1990
- A review of second-look laparotomy for ovarian cancerGynecologic Oncology, 1986
- RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMAThe Lancet, 1984
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958